Submit Your Feeds

Business News • PR NewsWire • ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin

ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin

LEUVEN, Belgium, June 7, 2010 /PRNewswire-FirstCall/ -- - Data Presented Show Microplasmin Cures Approximately 50% of Patients With Macular Hole ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for

View More : http://www.prnewswire.com/news-releases/thrombogenics-presents-new-exciting-microplasmin-phase-iii-data-at-the-world-oph...
Releted News by prnewswire
Local 223 Utility Workers Union of America (UWUA) Reach Tentative Agreement With DTE Energy
DTE Energy and Local 223 UWUA Union Leaders Reach Tentative Agreement
ThromboGenics Presents New Exciting Microplasmin Phase III Data at the World Ophthalmology Congress (WOC) in Berlin
Pieris AG Appoints Chief Scientific Officer
TSMC Extends Open Innovation Platform(TM)
Home Sitemap Contact Us
© businessNewsNewsNews.com